Clinical trial · Observational
The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer
NCT06381895CI-TRIAL-00076442completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to develop an radiomic model based on CT images to evaluate markers of the bladder cancer microenvironment, such as TSR,TIL, and IP. Secondly, the association of the radiomic model with clinical outcomes and immunotherapy response was investigated.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Immunotherapy | — | UNRESOLVED | — |
| Radiomics | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- 1
- description
- Sun Yat-sen Memorial Hospital cohort
- label
- 2
- description
- Third Affiliated Hospital of Sun Yat-sen University cohort
- label
- 3
- description
- Sun Yat-sen University Cancer Center cohort
Primary outcomes (1)
- measure
- Tumour-infiltrating lymphocytes (TIL)
- timeFrame
- 1 year
- description
- TILs were evaluated using paraffin-embedded tumour tissue samples stained with H\&E according to established protocols.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. At least 18 years of age; 2. Performing TURB-t or RC during 2010-2022; 3. The primary lesion was located in the bladder, and the pathological diagnosis was urothelial carcinoma; 4. Complete clinical information, pathological data, preoperative pelvic enhanced CT and follow-up records; Exclusion Criteria: 1. Patients with distant metastasis; 2. Combined with other malignant tumors or malignant tumor treatment history 3. Malignant tumors of upper urinary tract; 4. Clinical information, pathological data, preoperative pelvic enhanced CT and follow-up records were missing; 5. Other situations in which the researcher considers it inappropriate to participate in this study.
References
Publications (1)
- DERIVEDChen K, Li X, Liu L, Wang B, Liang W, Chen J, Gao M, Huang X, Liu B, Sun X, Yang T, Zhao X, He W, Luo Y, Huang J, Lin T, Zhong W. Correlation of noninvasive imaging of tumour-infiltrating lymphocytes with survival and BCG immunotherapy response in patients with bladder cancer: a multicentre cohort study. Int J Surg. 2025 Jan 1;111(1):920-931. doi: 10.1097/JS9.0000000000001999. PMID 40053821